U.S. patent application number 15/846663 was filed with the patent office on 2018-04-19 for administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders.
The applicant listed for this patent is GALDERMA RESEARCH & DEVELOPMENT. Invention is credited to Janusz CZERNIELEWSKI, Michael GRAEBER.
Application Number | 20180104203 15/846663 |
Document ID | / |
Family ID | 27806678 |
Filed Date | 2018-04-19 |
United States Patent
Application |
20180104203 |
Kind Code |
A1 |
GRAEBER; Michael ; et
al. |
April 19, 2018 |
ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC
ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS
Abstract
Dermatological disorders having an inflammatory or proliferative
component are treated with pharmaceutical compositions containing
on the order of 0.3% by weight of
6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene)
or salt thereof, formulated into pharmaceutically acceptable media
therefor, advantageously topically applicable gels, creams or
lotions.
Inventors: |
GRAEBER; Michael;
(Lawrenceville, NJ) ; CZERNIELEWSKI; Janusz;
(Biot, FR) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
GALDERMA RESEARCH & DEVELOPMENT |
Biot |
|
FR |
|
|
Family ID: |
27806678 |
Appl. No.: |
15/846663 |
Filed: |
December 19, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15175188 |
Jun 7, 2016 |
9872842 |
|
|
15846663 |
|
|
|
|
14222185 |
Mar 21, 2014 |
9381179 |
|
|
15175188 |
|
|
|
|
12902972 |
Oct 12, 2010 |
8703820 |
|
|
14222185 |
|
|
|
|
12437008 |
May 7, 2009 |
7834060 |
|
|
12902972 |
|
|
|
|
10937612 |
Sep 10, 2004 |
7579377 |
|
|
12437008 |
|
|
|
|
PCT/EP2003/003246 |
Mar 12, 2003 |
|
|
|
10937612 |
|
|
|
|
60370223 |
Apr 8, 2002 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 8/362 20130101;
A61K 31/203 20130101; A61Q 19/007 20130101; A61K 47/10 20130101;
A61K 8/36 20130101; C07C 2603/74 20170501; A61K 9/08 20130101; A61K
47/183 20130101; Y10S 514/859 20130101; A61K 47/34 20130101; A61P
9/06 20180101; A61P 17/06 20180101; A61Q 17/04 20130101; A61P 17/18
20180101; A61P 17/12 20180101; A61K 47/06 20130101; A61P 17/00
20180101; A61K 47/14 20130101; A61Q 19/008 20130101; A61K 47/26
20130101; A61K 47/32 20130101; A61P 17/10 20180101; A61K 31/192
20130101; A61K 47/22 20130101; A61K 9/06 20130101; A61P 17/02
20180101; A61K 47/02 20130101; A61K 8/368 20130101; A61K 31/07
20130101; A61K 47/6903 20170801; A61K 9/0014 20130101 |
International
Class: |
A61K 31/192 20060101
A61K031/192; A61Q 19/00 20060101 A61Q019/00; A61K 8/36 20060101
A61K008/36; A61K 8/362 20060101 A61K008/362; A61K 8/368 20060101
A61K008/368; A61Q 17/04 20060101 A61Q017/04; A61K 47/34 20060101
A61K047/34; A61K 47/32 20060101 A61K047/32; A61K 47/26 20060101
A61K047/26; A61K 47/22 20060101 A61K047/22; A61K 47/18 20060101
A61K047/18; A61K 47/14 20060101 A61K047/14; A61K 47/10 20060101
A61K047/10; A61K 47/06 20060101 A61K047/06; A61K 47/02 20060101
A61K047/02; A61K 31/07 20060101 A61K031/07; A61K 9/08 20060101
A61K009/08; A61K 9/06 20060101 A61K009/06; A61K 9/00 20060101
A61K009/00 |
Foreign Application Data
Date |
Code |
Application Number |
Mar 12, 2002 |
FR |
02/03070 |
Claims
1. A method for eliciting an early onset of action in regression of
non-inflammatory lesions in treating common acne afflicting an
individual's skin, the individual being in need of such treatment,
comprising topically administering daily to said individual an
anti-acne effective amount of a pharmaceutical composition which
consists essentially of: (1) 0.3% by weight of
6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid (adapalene) or
salt thereof; (2) one or more ingredients selected from the group
consisting of carbomer 940, carbomer 934, disodium edetate, methyl
paraben, propylene glycol, PEG methyl glucose sesquistearate, PEG
400, methyl glucose sesquistearate, cyclomethicone,
perhydrosqualene, propyl paraben, glycerol, sodium hydroxide,
ethanol and phenoxyethanol; (3) water; and (4) optionally, one or
more additive selected from the group consisting of wetting agents,
pH regulators, osmotic pressure modifiers, emulsifiers, UV-A and
UV-B screening agents and antioxidants, wherein said composition is
formulated into a pharmaceutically acceptable medium therefor, said
composition being a gel or a cream, said early onset of action
occurring by two weeks after treatment begins and being
demonstrated by regression of non-inflammatory lesions after two
weeks of treatment greater than that demonstrated by vehicle alone
or by a similar composition comprising 0.1% by weight of adapalene
after two weeks of treatment.
Description
CROSS-REFERENCE TO EARLIER APPLICATIONS
[0001] This application is a continuation of co-pending U.S. patent
application Ser. No. 15/175,188, filed Jun. 7, 2016, now allowed,
which is a continuation of co-pending U.S. patent application Ser.
No. 14/222,185, filed Mar. 21, 2014, now U.S. Pat. No. 9,381,179,
which is a continuation of U.S. patent application Ser. No.
12/902,972, filed Oct. 12, 2010, now U.S. Pat. No. 8,703,820, which
is a continuation of U.S. patent application Ser. No. 12/437,008,
filed May 7, 2009, now U.S. Pat. No. 7,834,060, which is a
continuation of U.S. patent application Ser. No. 10/937,612, filed
Sep. 10, 2004, now U.S. Pat. No. 7,579,377, which is a continuation
of PCT/EP03/03246 filed Mar. 12, 2003, and designating the United
States (published in English on Sep. 18, 2003 as WO 03/075908 A1),
which claims benefit of U.S. Provisional Application No.
60/370,223, filed Apr. 8, 2002, and also claims priority under 35
U.S.C. .sctn. 119 of FR-02/03070, filed Mar. 12, 2002, each earlier
application being hereby expressly incorporated by reference and
each assigned to the assignee hereof.
CROSS REFERENCE TO OTHER RELATED APPLICATIONS
[0002] See also co-pending U.S. patent application Ser. No.
12/103,182, filed Apr. 15, 2008, now U.S. Pat. No. 7,838,558, which
is a divisional application of earlier filed co-pending U.S. patent
application Ser. No. 10/937,612, filed Sep. 10, 2004, now U.S. Pat.
No. 7,579,377, and claims the same domestic and foreign priority as
claimed herein; and co-pending U.S. patent application Ser. No.
12/772,861, filed May 3, 2010, which is a division of U.S. patent
application Ser. No. 11/494,693, filed Jul. 28, 2006, now U.S. Pat.
No. 7,737,181, which is a continuation-in-part of earlier filed
co-pending U.S. patent application Ser. No. 10/937,612 filed Sep.
10, 2004, and claims the same domestic and foreign priority as
claimed herein; both of said applications also expressly
incorporated by reference herein and assigned to the assignee
hereof.
BACKGROUND OF THE INVENTION
Technical Field of the Invention
[0003] The present invention relates to the administration to
individuals in need of such treatment of
6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid, the
chemical structure of which is as follows:
##STR00001##
in pharmaceutical compositions, in particular dermatological
compositions, for the treatment of dermatological
ailments/afflictions having an inflammatory or proliferative
component.
Description of Background and/or Related and/or Prior Art
[0004] 6-[3-(1-Adamantyl)-4-methoxyphenyl]-2-naphthanoic acid
(hereinafter referred to as adapalene) is a retinoid derived from
naphthoic acid, having anti-inflammatory properties. This molecule
has been the subject of development for the topical treatment of
common acne and dermatoses sensitive to retinoids.
[0005] Adapalene is described in EP-0,199,636, and a process for
synthesizing same is described in EP-0,358,574, both assigned to
the assignee hereof.
[0006] The assignee hereof markets adapalene formulated at a weight
concentration of 0.1% in the form of an alcoholic lotion, an
aqueous gel and a cream. These compositions are suited for the
treatment of acne.
[0007] Finally, adapalene is described as having a beneficial
action on photodamaged skin (Photographic assessment of the effects
of adapalene 0.1% and 0.3% gels and vehicle on photodamaged skin.
M. Goldfarb et al., Clinical Dermatology, Vienna, Austria, May
2000).
SUMMARY OF THE INVENTION
[0008] Novel pharmaceutical compositions have now been developed
containing adapalene at a weight concentration of 0.3% formulated
into pharmaceutically acceptable media therefor, useful for the
treatment (regime or regimen) of dermatological ailments,
conditions or afflictions having an inflammatory or proliferative
component. Specifically, it has now surprisingly been shown that,
in addition to exhibiting better therapeutic efficacy compared to
known compositions, the compositions according to the invention
exhibits good tolerance, comparable to those of the known
compositions with a lower concentration of active principle.
[0009] The results regarding tolerance observed in trials relating
to photo-damaged skin (indication "photodamage"), obtained on
individuals on average 65 years old, could not be exploited in the
context of the present invention. Specifically, as regards use of
adapalene on young individuals (in particular regarding acne with
populations of teenagers or young adults), the skin exhibits very
different physiopathological characteristics (presence of many
lesions, in particular inflammatory lesions, modifying skin
permeability, hypercornification of the follicular channel, immuno
response, bacterial colonization of the skin (P. acnes), sebaceous
hyperplasia with hyperseborrhea).
BRIEF DESCRIPTION OF THE DRAWINGS
[0010] FIG. 1 is a graph illustrating regression in the number of
total lesions for 0.30% adapalene gel, as compared to 0.10%
adapalene gel and the gel vehicle without active ingredient, over a
12-week treatment period in groups of patients suffering from
acne.
[0011] FIG. 2 is a graph illustrating regression in the number of
inflammatory lesions for 0.30% adapalene gel, as compared to 0.10%
adapalene gel and the gel vehicle without active ingredient, over a
12-week treatment period in groups of patients suffering from
acne.
[0012] FIG. 3 is a graph illustrating regression in the number of
non-inflammatory lesions for 0.30% adapalene gel, as compared to
0.10% adapalene gel and the gel vehicle without active ingredient,
over a 12-week treatment period in groups of patients suffering
from acne.
DETAILED DESCRIPTION OF BEST MODE AND SPECIFIC/PREFERRED
EMBODIMENTS OF THE INVENTION
[0013] Thus, the present invention features formulating
6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene),
or its salts, into pharmaceutical compositions useful for the
treatment of dermatological ailments, conditions or afflictions
having an inflammatory or proliferative component, such
pharmaceutical compositions comprising 0.3% by weight of adapalene
relative to the total weight of the composition.
[0014] The term "adapalene salts" is intended to mean the salts
formed with a pharmaceutically acceptable base, in particular
organic bases such as sodium hydroxide, potassium hydroxide and
aqueous ammonia, or organic bases such as lysine, arginine or
N-methylglucamine.
[0015] The term "adapalene salts" is also intended to mean the
salts formed with fatty amines such as dioctylamine and
stearylamine.
[0016] The administration of the compositions according to the
invention may be carried out enterally, parenterally, topically or
occularly.
[0017] The pharmaceutical compositions according to the invention
are preferably administered topically.
[0018] Enterally, the pharmaceutical composition may be in the form
of tablets, gelatin capsules, dragees, syrups, suspensions,
solutions, powders, granules, emulsions, or suspensions of
microspheres or nanospheres or of lipid or polymeric vesicles for
controlled release. Parenterally, the pharmaceutical composition
may be in the form of solutions or suspensions for infusion or for
injection.
[0019] Topically, the pharmaceutical compositions according to the
invention are more particularly suited for treatment of the skin
and the mucous membranes, and may be in the form of ointments,
creams, milks, pomades, powders, impregnated pads, solutions, gels,
sprays, lotions or suspensions. They may also be in the form of
suspensions of microspheres or nanospheres or of lipid or polymeric
vesicles, or of polymeric patches and hydrogels for controlled
release. These compositions for topical application may be in
anhydrous form, in aqueous form or in the form of an emulsion.
[0020] In a preferred embodiment of the invention, the
pharmaceutical composition according to the invention is in the
form of a gel, a cream or a lotion.
[0021] In particular, the pharmaceutical composition may be an
aqueous gel containing in particular one or more ingredients
selected from among Carbomer 940 (BF Goodrich, Carbopol 980) and
propylene glycol, or a cream containing in particular one or more
ingredients selected from among perhydrosqualene, cyclomethicone,
PEG-20 methyl glucose sequistearate and methyl glucose
sequistearate, or a polyethylene glycol-based alcoholic lotion.
[0022] The pharmaceutical compositions according to the invention
may also contain inert additives or combinations of these
additives, such as [0023] wetting agents; [0024] flavor enhancers;
[0025] preservatives such as para-hydroxybenzoic acid esters;
[0026] stabilizers; [0027] moisture regulators; [0028] pH
regulators; [0029] osmotic pressure modifiers; [0030] emulsifiers;
[0031] UV-A and UV-B screening agents; [0032] and antioxidants,
such as .alpha.-tocopherol, butylhydroxyanisole or
butylhydroxytoluene, superoxide dismutase, ubiquinol or certain
metal chelating agents.
[0033] Of course, those skilled in the art will take care to select
the optional compound(s) to be added to these compositions in such
a way that the advantageous properties intrinsically associated
with the present invention are not, or are not substantially,
adversely affected by the envisaged addition.
[0034] The formulation of adapalene into pharmaceutical
compositions according to the invention is especially intended for
the treatment of dermatological ailments, conditions and
afflictions having an inflammatory or proliferative component,
selected from the group consisting of: [0035] common acne,
comedones, polymorphous acne, nodulocystic acne, acne conglobata,
secondary acne such as solar, drug-related or occupational acne;
[0036] widespread and/or severe forms of psoriasis, ichtyoses and
ichtyosiform states; [0037] Darier's disease; [0038] actinic
keratoses; [0039] palmo plantar keratoderma and keratosis pilaris;
[0040] leucoplasias and leucoplasiform states, lichen planus;
[0041] any benign or malignant, severe and extensive dermatological
preparations.
[0042] The compositions according to the invention are particularly
suitable for the treatment of acne, such as common acne, and in
particular for the treatment of common acne of moderate to
moderately severe intensity.
[0043] Various formulations of compositions comprising 0.3% of
adapalene will now be given, it being understood that same are
intended only as illustrative and in nowise limitative. Also given
are results showing the therapeutic effects of the compositions
according to the invention and the good tolerance to same by the
treated patients.
[0044] In said examples to follow, all parts and percentages are
given by weight, unless otherwise indicated.
EXAMPLE 1--FORMULATION FOR TOPICAL ADMINISTRATION
[0045] In this example, various specific topical formulations
comprising 0.3% of adapalene are illustrated.
[0046] The adapalene of the present example is provided by
Sylachim, Division Finorga (product reference CF9611996).
[0047] (a) Cream:
TABLE-US-00001 Adapalene 3 mg Carbomer 934 (BF Goodrich 4.5 mg
Carbopol 974) Disodium edetate 1 mg PEG methyl glucose
sesquistearate 35 mg Methyl glucose sesquistearate 35 mg Glycerol
30 mg Methyl paraben 2 mg Cyclomethicone 130 mg Perhydrosqualene 60
mg Phenoxyethanol 5 mg Propyl paraben 1 mg Sodium hydroxide
quantity required for pH 6.5 +/- 0.3 Purified water q.s. 1 g
[0048] (b) Lotion:
TABLE-US-00002 Adapalene 3 mg PEG 400 700 mg Ethanol q.s. 1 g
[0049] (c) Aqueous Gel:
TABLE-US-00003 Adapalene 3 mg Carbomer 940 (BF Goodrich 11 mg
Carbopol 980) Disodium edetate 1 mg Methyl paraben 2 mg Poloxamer
124 2 mg Propylene glycol 40 mg Sodium hydroxide: amount required
to obtain a pH 5.0 +/- 0.3 Purified water q.s. 1 g
EXAMPLE 2--EFFECTIVENESS OF 0.3% ADAPALENE GEL AND COMPARISON WITH
THE 0.1% ADAPALENE GEL
[0050] Tests were carried out on a population consisting of
patients suffering from acne. In this population, three groups were
differentiated; the first received a daily topical application of
the 0.3% adapalene gel, the second a daily topical application of
the 0.1% adapalene gel in the same vehicle, and the third is a
control group which receives a daily topical application of the gel
corresponding to the composition of the first two gels but
containing no active agent.
[0051] FIGS. 1 to 3 provide the results obtained in terms of
regression of the number of lesions according to their nature.
[0052] These observations lead to the following conclusions: [0053]
the 0.3% adapalene gel acts more rapidly than the 0.1% adapalene
gel; specifically, from the fourth week of treatment, a difference
is noted between the effectiveness of the 0.1% adapalene gel and
the 0.3% adapalene gel; [0054] the 0.3% adapalene gel produces a
clearly greater therapeutic effect after 8 weeks of treatment.
EXAMPLE 3--TOLERANCE REGARDING THE 0.3% ADAPALENE GEL
[0055] 1. Measurement of the Plasma Concentration of Adapalene:
[0056] Eight individuals suffering from common acne of medium to
moderately severe intensity are treated for 10 days with 2 g of
0.3% adapalene gel applied daily over 1000 cm.sup.2 of skin to be
treated (face, chest and back).
[0057] Blood samples are taken on the days 1, 2, 4, 6, 8 and 10.
During day 10, and following the final application, samples are
taken at 1, 2, 6, 8, 10, 12, 16 and 24 hours.
[0058] The plasma concentration of total adapalene (free and
conjugated) in these samples is determined using the following
protocol: [0059] enzymatic hydrolysis with a mixture of
.beta.-glucurodinase and arylsulfatase; [0060] liquid-liquid
extraction; [0061] passage through HPLC (high performance liquid
chromatography); and then fluorometric detection.
[0062] This method makes it possible to detect a minimum
concentration of 0.15 ng/ml and permits quantification of the
adapalene for a minimum concentration of 0.25 ng/ml.
CONCLUSION
[0063] The plasma concentrations of adapalene measured after 10
days of treatment are very low and confirm the safety of daily use
of the 0.3% adapalene gel.
[0064] 2 a) Clinical Observation of the Side Effects Caused by
Topical Administration of the 0.3% Adapalene Gel:
[0065] Two types of observation could be made: [0066] firstly,
monitoring of the patients treated within the framework of point 1
of the present Example 3 made it possible to note that tolerance to
the 0.3% adapalene gel was good for all patients. They all showed
signs of dryness of the skin and of desquamation with a maximum on
the seventh day of treatment, these symptoms then decrease up to
the end of the treatment.
[0067] 2 b) Furthermore, Reference May Also Be Made to the Tests
Described in Example 2 Above:
[0068] In parallel to the measurements of effectiveness, the
experimenters recorded the possible side effects caused, firstly,
by topical application of the 0.3% adapalene gel and those caused,
secondly, by application of the 0.1% adapalene gel; finally, the
same observations were made on a control population to which a gel
without active principle was administered.
[0069] These observations are reported in the table below.
TABLE-US-00004 Local undesirable 0.3% adapalene 0.1% adapalene
Vehicle gel effects gel (N = 70) gel (N = 70) (N = 74) Skin and
secondary 31 (44.3%) 28 (40.0%) 5 (6.8%) structures (nails, hair)
Dry skin 16 (22.9%) 13 (18.6%) 2 (2.7%) Erythema 8 (11.4%) 3 (4.3%)
0 (0.0%) Skin discomfort 8 (11.4%) 7 (10.0%) 0 (0.0%) Desquamation
6 (8.6%) 5 (7.1%) 0 (0.0%) Dermatitis 3 (4.3%) 1 (1.4%) 0 (0.0%)
Pruritus 3 (4.3%) 1 (1.4%) 1 (1.4%) Irritant dermatitis 2 (2.9%) 7
(10.0%) 0 (0.0%) Local allergic reactions 1 (1.4%) 0 (0.0%) 0
(0.0%) Pediculosis 1 (1.4%) 0 (0.0%) 0 (0.0%) Contact dermatitis 1
(1.4%) 0 (0.0%) 0 (0.0%) Insolation 1 (1.4%) 3 (4.3%) 1 (1.4%)
Burning sensation 1 (1.4%) 0 (0.0%) 0 (0.0%) Urticaria 1 1.4%) 0
(0.0%) 0 (0.0%) Infection 1 (1.4%) 0 (0.0%) 0 (0.0%) Excoriation 0
(0.0%) 0 (0.0%) 1 (1.4%) Eczema 0 (0.0%) 0 (0.0%) 1 (1.4%) Oedema 0
(0.0%) 1 (1.4%) 0 (0.0%)
[0070] From this table, it is noted that the occurrence of
undesirable side effects is statistically the same for the two gels
with the different concentrations of active agent. The intensity of
the undesirable side effects is average, which leads to the
conclusion that the two gels are well-tolerated by the
patients.
[0071] On the basis of these observations, it may be concluded that
patients suffering from common acne can be treated with 0.3%
adapalene gel, such an exposure to adapalene being described as
weak or very weak under clinical conditions.
[0072] It therefore ensues from these various studies that a
pharmaceutical composition containing 0.3% of adapalene exhibits a
benefit/risk ratio which makes it particularly suitable for the
treatment of dermatological maladies having an inflammatory or
proliferative component, and in particular, common acne.
[0073] Each patent, patent application, publication and literature
article/report cited or indicated herein is hereby expressly
incorporated by reference.
[0074] While the invention has been described in terms of various
specific and preferred embodiments, the skilled artisan will
appreciate that various modifications, substitutions, omissions,
and changes may be made without departing from the spirit thereof.
Accordingly, it is intended that the scope of the present invention
be limited solely by the scope of the following claims, including
equivalents thereof.
* * * * *